- Home
- IGR vs QURE Comparison
IGR vs QURE Comparison
Compare IGR & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGR
- QURE
- Stock Information
- Founded
- IGR 2004
- QURE 1998
- Country
- IGR United States
- QURE Netherlands
- Employees
- IGR N/A
- QURE N/A
- Industry
- IGR Finance Companies
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- IGR Finance
- QURE Health Care
- Exchange
- IGR Nasdaq
- QURE Nasdaq
- Market Cap
- IGR 752.8M
- QURE 725.4M
- IPO Year
- IGR N/A
- QURE 2007
- Fundamental
- Price
- IGR $4.92
- QURE $16.18
- Analyst Decision
- IGR
- QURE Strong Buy
- Analyst Count
- IGR 0
- QURE 10
- Target Price
- IGR N/A
- QURE $36.90
- AVG Volume (30 Days)
- IGR 747.7K
- QURE 1.2M
- Earning Date
- IGR 01-01-0001
- QURE 07-29-2025
- Dividend Yield
- IGR 13.93%
- QURE N/A
- EPS Growth
- IGR N/A
- QURE N/A
- EPS
- IGR N/A
- QURE N/A
- Revenue
- IGR N/A
- QURE $14,337,000.00
- Revenue This Year
- IGR N/A
- QURE N/A
- Revenue Next Year
- IGR N/A
- QURE $278.91
- P/E Ratio
- IGR N/A
- QURE N/A
- Revenue Growth
- IGR N/A
- QURE N/A
- 52 Week Low
- IGR $3.88
- QURE $4.45
- 52 Week High
- IGR $5.70
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- IGR 43.69
- QURE 65.00
- Support Level
- IGR $4.80
- QURE $12.89
- Resistance Level
- IGR $4.94
- QURE $14.23
- Average True Range (ATR)
- IGR 0.07
- QURE 1.03
- MACD
- IGR 0.01
- QURE 0.23
- Stochastic Oscillator
- IGR 72.50
- QURE 88.91
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.